CLINICAL TRIALS PROFILE FOR PF-06882961
✉ Email this page to a colleague
Clinical Trials for PF-06882961
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03309241 ↗ | First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects | Completed | Pfizer | Phase 1 | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961. |
| NCT03492697 ↗ | A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961 | Completed | Pfizer | Phase 1 | This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects. |
| NCT03538743 ↗ | 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes | Completed | Pfizer | Phase 1 | This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days. |
| NCT03985293 ↗ | A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus | Completed | Pfizer | Phase 2 | This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961. |
| NCT04495140 ↗ | Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961 | Completed | Pfizer | Phase 1 | This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of PF-06882961 and fraction absorbed of [14C]PF-06882961 in reference to intravenous [14C]PF-06882961 in healthy male participants. |
| NCT04552470 ↗ | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus | Completed | Pfizer | Phase 1 | This is a Phase 1, randomized, double blind (sponsor open), parallel, placebo controlled, twice daily oral dosing study of PF 06882961 in adult Japanese participants with T2DM inadequately controlled on diet and exercise alone. |
| NCT04604496 ↗ | STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT | Recruiting | Pfizer | Phase 1 | The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961 |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-06882961
Condition Name
Clinical Trial Locations for PF-06882961
Trials by Country
Clinical Trial Progress for PF-06882961
Clinical Trial Phase
Clinical Trial Sponsors for PF-06882961
Sponsor Name
